Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allarity Therapeutics, Inc. - Common stock (NQ: ALLR )

0.5654 -0.0104 (-1.81%)
Streaming Delayed Price Updated: 2:10 PM EDT, May 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Allarity Therapeutics, Inc. - Common stock

< Previous 1 2 Next >
This Combination Therapy Could Help Change Cancer Treatment - Take A Deeper Look Into Allarity Therapeutics' Trial
Via ACCESSWIRE
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Reports Third Quarter 2022 Financial Results
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-Generation” Diagnostics Platform
Once brought into its pipeline, Allarity uses its DRP® platform to develop companion diagnostics alongside each drug to improve the treatments in a personalized medicine approach. Earlier this year,... 
Via TheNewswire.com
Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics (NASDAQ: ALLR): Diamond in the Rough
New York, United States - 08-11-2022 (PR Distribution™) - 
Via PR Distribution
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.